189 related articles for article (PubMed ID: 27683974)
1. Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.
Kost SE; Bouchard ED; LaBossière É; Ye X; Queau ML; Liang WS; Banerji V; Gibson SB; Katyal S; Johnston JB
Leuk Res; 2016 Nov; 50():63-71. PubMed ID: 27683974
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with nucleoside analogs and alkylating agents.
Johnston JB; Verburg L; Shore T; Williams M; Israels LG; Begleiter A
Leukemia; 1994 Apr; 8 Suppl 1():S140-3. PubMed ID: 8152282
[TBL] [Abstract][Full Text] [Related]
3. Chlorambucil in chronic lymphocytic leukemia: mechanism of action.
Begleiter A; Mowat M; Israels LG; Johnston JB
Leuk Lymphoma; 1996 Oct; 23(3-4):187-201. PubMed ID: 9031099
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia.
Begleiter A; Wang H; Verburg L; Lee K; Israels LG; Mowat MR; Johnston JB
Leukemia; 1996 Dec; 10(12):1959-65. PubMed ID: 8946937
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin.
Christodoulopoulos G; Muller C; Salles B; Kazmi R; Panasci L
Cancer Res; 1998 May; 58(9):1789-92. PubMed ID: 9581813
[TBL] [Abstract][Full Text] [Related]
7. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
Johnston JB; Kabore AF; Strutinsky J; Hu X; Paul JT; Kropp DM; Kuschak B; Begleiter A; Gibson SB
Oncogene; 2003 Nov; 22(51):8356-69. PubMed ID: 14614459
[TBL] [Abstract][Full Text] [Related]
8. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
Silber R; Degar B; Costin D; Newcomb EW; Mani M; Rosenberg CR; Morse L; Drygas JC; Canellakis ZN; Potmesil M
Blood; 1994 Nov; 84(10):3440-6. PubMed ID: 7949099
[TBL] [Abstract][Full Text] [Related]
10. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro.
Begleiter A; Verburg L; Ashique A; Lee K; Israels LG; Mowat MR; Johnston JB
Leukemia; 1995 Nov; 9(11):1875-81. PubMed ID: 7475278
[TBL] [Abstract][Full Text] [Related]
12. Imatinib sensitizes CLL lymphocytes to chlorambucil.
Aloyz R; Grzywacz K; Xu ZY; Loignon M; Alaoui-Jamali MA; Panasci L
Leukemia; 2004 Mar; 18(3):409-14. PubMed ID: 14712290
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
14. In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.
Morabito F; Callea I; Irrera G; Cartisano G; Dattola A; Rodinò A; Brugiatelli M
Eur J Haematol; 1997 May; 58(5):301-6. PubMed ID: 9222284
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
Shcherbina V; Gordiienko I; Shlapatska L; Ivanivska T; Sidorenko S
Exp Oncol; 2020 Mar; 42(1):16-24. PubMed ID: 32231196
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.
El-Mabhouh AA; Ayres ML; Shpall EJ; Baladandayuthapani V; Keating MJ; Wierda WG; Gandhi V
Blood; 2014 Jun; 123(24):3780-9. PubMed ID: 24747434
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia.
Kost SEF; Saleh A; Mejia EM; Mostafizar M; Bouchard EDJ; Banerji V; Marshall AJ; Gibson SB; Johnston JB; Katyal S
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31601046
[No Abstract] [Full Text] [Related]
18. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with purine nucleoside analogs.
Foss FM
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):31-5. PubMed ID: 10887642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
